International Journal of Research and Applied Innovations (IJRAI)

| ISSN: 2455-1864 | www.ijrai.com | editor@ijrai.com | A Bimonthly, Scholarly and Peer-Reviewed Journal |

||Volume 3, Issue 3, May – June 2020||

DOI:10.15662/IJRAI.2020.0303001

AI-Assisted Drug Repurposing Pipelines for Viral Diseases

Mitali Anuradha Chowdhury

JNN College of Engineering, Shivamogga, Karnataka, India

ABSTRACT: The rapid emergence of novel viral infections, such as COVID-19, has underscored the urgent need for expedited therapeutic interventions. Traditional drug discovery processes are time-consuming and costly, often taking over a decade and billions of dollars to develop new drugs. In contrast, drug repurposing offers a promising alternative by identifying existing, approved drugs that can be repurposed for new therapeutic indications. Artificial Intelligence (AI) has emerged as a pivotal tool in this domain, facilitating the identification of potential drug candidates through advanced computational methods.

AI-assisted drug repurposing pipelines leverage various techniques, including machine learning, deep learning, and network-based approaches, to analyze vast biological datasets. These pipelines integrate data from multiple sources, such as gene expression profiles, protein-protein interaction networks, and drug-target databases, to predict novel drug-disease associations. By employing algorithms that can process and interpret complex biological data, AI models can identify potential therapeutic candidates more efficiently than traditional methods.

In the context of viral diseases, AI has been utilized to predict existing drugs that may inhibit viral replication or modulate host immune responses. For instance, during the early stages of the COVID-19 pandemic, AI models were employed to identify potential treatments by analyzing the virus's genetic sequence and comparing it with existing drug databases. Such approaches have led to the identification of promising candidates that are currently undergoing clinical trials.

This paper provides an overview of AI-assisted drug repurposing pipelines, highlighting their methodologies, applications in viral diseases, and the challenges associated with their implementation. By examining case studies and recent advancements, we aim to underscore the potential of AI in accelerating the development of therapeutic agents for viral infections.

KEYWORDS: AI-assisted drug repurposing, Viral diseases , Machine learning, Deep learning, Network-based approaches Drug discovery, COVID-19

I. INTRODUCTION

The emergence of novel viral infections poses significant challenges to global health, necessitating rapid development of effective therapeutic interventions. Traditional drug discovery processes are often lengthy and resource-intensive, making them ill-suited for addressing immediate public health threats. Drug repurposing, the process of identifying existing drugs that can be used for new therapeutic indications, offers a more expedient approach. By leveraging the safety profiles and established pharmacokinetics of approved drugs, repurposing can potentially shorten development timelines and reduce costs.

Artificial Intelligence (AI) has revolutionized various fields, including drug discovery, by enabling the analysis of large and complex biological datasets. In the realm of drug repurposing, AI models can predict potential drug-disease associations by integrating data from diverse sources, such as gene expression profiles, protein-protein interaction networks, and drug-target databases. These models employ various techniques, including machine learning algorithms, deep learning architectures, and network-based approaches, to identify existing drugs that may be effective against novel viral pathogens.

The application of AI in drug repurposing for viral diseases has gained prominence, particularly in the wake of the COVID-19 pandemic. Early in the pandemic, AI models were utilized to analyze the genetic sequence of the SARS-CoV-2 virus and compare it with existing drug databases, leading to the identification of potential therapeutic candidates. This

| ISSN: 2455-1864 | www.ijrai.com | editor@ijrai.com | A Bimonthly, Scholarly and Peer-Reviewed Journal |

||Volume 3, Issue 3, May – June 2020||

DOI:10.15662/IJRAI.2020.0303001

approach not only accelerated the identification process but also provided insights into the mechanisms of action of existing drugs against the virus.

This paper aims to explore the methodologies employed in AI-assisted drug repurposing pipelines, their applications in viral diseases, and the challenges and limitations associated with their use. By examining these aspects, we seek to highlight the potential of AI in transforming the landscape of drug discovery and development for viral infections.

II. LITERATURE REVIEW

The application of Artificial Intelligence (AI) in drug repurposing has garnered significant attention in recent years, particularly in the context of viral diseases. Traditional drug discovery methods are often time-consuming and costly, whereas AI offers the potential to expedite the identification of therapeutic candidates by analyzing large-scale biological data.

Machine learning (ML) algorithms have been extensively utilized in drug repurposing studies. These algorithms can process complex datasets, such as gene expression profiles and chemical properties of drugs, to predict potential drug-disease associations. For instance, studies have employed ML techniques to identify existing antiviral drugs that could be repurposed for emerging viral infections by analyzing patterns in biological data.

Deep learning (DL), a subset of ML, has also been applied in drug repurposing efforts. DL models, particularly convolutional neural networks (CNNs) and recurrent neural networks (RNNs), have been used to analyze molecular structures and predict interactions between drugs and viral targets. These models can learn hierarchical representations of data, enabling them to capture intricate patterns that may be indicative of therapeutic efficacy.

Network-based approaches have further enhanced AI-assisted drug repurposing pipelines. By constructing and analyzing biological networks, researchers can identify potential drug targets and predict how existing drugs might interact with these targets. Such approaches have been instrumental in uncovering novel drug-disease associations, especially in the context of complex viral diseases.

Despite the promising applications of AI in drug repurposing, several challenges remain. Issues such as data quality, model interpretability, and the need for extensive validation studies must be addressed to ensure the reliability and efficacy of AI-predicted drug candidates. Ongoing research aims to refine AI methodologies and overcome these challenges to facilitate the successful repurposing of drugs for viral diseases.

III. RESEARCH METHODOLOGY

The research methodology for AI-assisted drug repurposing pipelines involves several key steps, each contributing to the identification and validation of potential therapeutic candidates for viral diseases.

1. **Data Collection**: The first step involves gathering comprehensive biological data, including gene expression profiles, protein-protein interaction networks, and chemical properties of existing drugs. Public databases such as PubChem, DrugBank, and the Gene Expression Omnibus (GEO) serve as valuable resources for this purpose.
2. **Data Preprocessing**: Collected data undergo preprocessing to ensure quality and consistency. This step includes normalization of gene expression data, removal of duplicates, and handling of missing values to prepare the datasets for analysis.
3. **Feature Extraction**: Relevant features are extracted from the preprocessed data. For gene expression data, features may include differentially expressed genes, while for chemical properties, features could encompass molecular descriptors such as molecular weight and lipophilicity.
4. **Model Development**: Machine learning algorithms, such as support vector machines (SVM), random forests, and neural networks, are employed to develop predictive models. These models learn patterns in the data to predict potential drug-disease associations.
5. **Model Validation**: The developed models are validated using separate datasets to assess their accuracy and generalizability. Cross-validation techniques are commonly used to evaluate model performance.

| ISSN: 2455-1864 | www.ijrai.com | editor@ijrai.com | A Bimonthly, Scholarly and Peer-Reviewed Journal |

||Volume 3, Issue 3, May – June 2020||

DOI:10.15662/IJRAI.2020.0303001

6. **Drug Prediction**: The validated models are applied to predict existing drugs that may be effective against the target viral disease. These predictions are ranked based on the model's confidence scores.
7. **In Silico Validation**: Predicted drug candidates undergo in silico validation through molecular docking studies to assess their binding affinity to viral targets.
8. **In Vitro and In Vivo Validation**: Promising drug candidates identified through in silico studies are subjected to laboratory experiments (in vitro) and animal studies (in vivo) to evaluate their efficacy and safety.